AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, HIV Infection, Plasmablastic Lymphoma, Primary Effusion Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Conditions
Brief summary
This partially randomized phase I/II trial studies the side effects and the best dose of vorinostat when given together with combination chemotherapy and rituximab to see how well it works compared to combination chemotherapy alone in treating patients with human immunodeficiency virus-related diffuse large B-cell non-Hodgkin lymphoma or other aggressive B-cell lymphomas. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving vorinostat together with combination chemotherapy and rituximab may kill more cancer cells.
Detailed description
PRIMARY OBJECTIVES: I. Determine the recommended phase II dose (RPTD) of vorinostat that may be used in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride and rituximab (R-DA-EPOCH) (in high-risk disease) in participants with human immunodeficiency virus (HIV)-associated aggressive cluster of differentiation (CD)20 positive non-Hodgkin lymphoma (NHL). (Phase I) II. Determine the overall toxicity rates of R-DA-EPOCH (in high-risk disease) with and without vorinostat. (Phase II) III. Determine the efficacy of the combinations of R-DA-EPOCH (in high-risk disease) with and without vorinostat in HIV-associated aggressive CD20 positive NHL using complete response (CR) rates as study endpoints. (Phase II) SECONDARY OBJECTIVES: I. Determine 1-year event-free survival (EFS) and 1 year overall survival (OS). II. Assess the effect of vorinostat and chemotherapy on latent HIV in memory T cells. III. Assess the effect of vorinostat and/or chemotherapy on HIV, Epstein-Barr virus (EBV), and human herpes virus 8 (HHV-8) viral loads on banked specimens. IV. Assess the effect of vorinostat and/or chemotherapy on T-cell subsets (CD4 and CD8) and plasma immunoglobulin levels. V. Assess the effect of concurrent vorinostat and rituximab on plasma steady-state concentrations of etoposide, doxorubicin (doxorubicin hydrochloride), and vincristine (vincristine sulfate) (on Phase I only). VI. Perform wide human gene expression profiling and methylation studies in tumors banked at baseline. VII. Evaluate EBV and HHV-8 gene expression patterns in positive tumors banked at baseline. OUTLINE: This is a phase I, dose-escalation study of vorinostat followed by a phase II study. PHASE I: Patients receive vorinostat orally (PO) once daily (QD) on days 1-5; rituximab intravenously (IV) on day 1; etoposide IV over 24 hours, doxorubicin hydrochloride IV over 24 hours, and vincristine sulfate IV over 24 hours on days 1-4; prednisone PO daily on days 1-5; and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. PHASE II: Patients are randomized to 1 of 2 treatment arms. ARM A (VR-DA-EPOCH): Patients receive vorinostat, rituximab, etoposide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and cyclophosphamide as in Phase I. ARM B (DA-R-EPOCH): Patients receive rituximab, etoposide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and cyclophosphamide as in Arm A. In all arms, treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Interventions
DRUGCyclophosphamide
Given IV
DRUGDoxorubicin Hydrochloride
Given IV
DRUGEtoposide
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
OTHERPharmacological Study
Correlative studies
DRUGPrednisone
Given PO
BIOLOGICALRituximab
Given IV
DRUGVincristine Sulfate
Given IV
DRUGVorinostat
Given PO
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants with histologically or cytologically documented diffuse large B-cell lymphoma (DLBCL) must meet at least 1 of the following risk criteria: * Age-adjusted International Prognostic Index (IPI) score: 2-3 * Ki-67 \>= 80% * Histologically, or cytologically documented activated B-cell-like (ABC, also known as post-GCB) subtype * Double hit variant, defined as having v-myc avian myelocytomatosis viral oncogene homolog (MYC) gene rearrangement in the presence of B-cell chronic lymphocytic leukemia (CLL)/lymphoma (BCL) 2 or BCL6 gene rearrangement * Other aggressive non-DLBCL non-Burkitt non-Hodgkin B-cell lymphoma variants as defined by the 2008 World Health Organization (WHO) classification, including rare CD20 negative B-cell lymphomas (i.e. plasmablastic lymphoma, and primary effusion lymphoma) are also eligible; grade 3B follicular lymphoma is also eligible as long as one the above risk criteria is met * Participants who are untreated or who received a maximum of one (1) cycle of combination chemotherapy, including rituximab-containing regimens, prior are eligible; the start of previous chemotherapy cycle must occur at least 21 days prior to beginning treatment under this protocol, and such cycle will count towards the total maximum of 6 cycles under this study * Documentation of HIV infection at any time prior to study entry; documentation may be molecular (detectable viral ribonucleic acid \[RNA\] by polymerase chain reaction \[PCR\]), serologic (positive enzyme-linked immunosorbent assay \[ELISA\] and positive Western blot), or other federally approved licensed HIV test; prior documentation of HIV seropositivity is acceptable * All stages of disease * Measurable or non-measurable tumor parameter(s); non-measurable tumor parameters are defined as not having bidimensional measurements (e.g., gastric or marrow involvement), but can be followed for response by other diagnostic tests such as gallium, positron emission tomography (PET) imaging, and/or bone marrow biopsy * Performance status (PS) 0, 1, or 2 per the Eastern Cooperative Oncology Group (ECOG) performance status scale (Karnofsky performance score \>= 50%) * Able to provide informed consent * Total bilirubin =\< 1.5 institutional upper limit of normal (ULN), unless elevated secondary to lymphomatous involvement of liver or biliary system, or due to other HIV medications (e.g., indinavir, tenofovir, or atazanavir); for direct bilirubin \> 1.2 due to hepatic involvement by tumor for the initial dose of EPOCH drug adjustment * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 times ULN (unless elevated due to secondary lymphomatous involvement of the liver) * Negative for hepatitis B, or if infected with hepatitis B, receiving anti-hepatitis B therapy; all participants will be required to be screened for hepatitis B and C; per Infectious Disease Society of America (IDSA) and American Association for the Study of Liver Diseases (AASD) guidelines, those participants that show no immunity, defined by the lack of hepatitis B surface antibody, and show evidence of chronic infection (i.e. hepatitis B surface antigen positive \[HBsAg+\], hepatitis B core antibody positive \[HBcore+\], hepatitis surface antibody negative \[HBsAB-\]) will be required to be on anti-hepatitis B therapy, during the study, in order to be eligible; participants will be permitted to enroll in the study provided liver function tests meet criteria, and there is no evidence of cirrhosis; the exact hepatitis B therapy will be at the discretion of the infection disease specialist or investigator; however all participants who present with acute hepatitis B or show normal transaminases and are HBsAg+ and immunoglobulin (Ig)M+ for hepatitis core antigen will not be eligible for trial enrollment; participants who are hepatitis C antibody positive, with or without a positive hepatitis C RNA level, will be permitted to enroll in the study provided liver function tests meet criteria, and have no evidence of cirrhosis; participants diagnosed with hepatitis C less than 6 months from trial enrollment, will be considered to have acute hepatitis C and will be excluded from study unless hepatitis (hep) C viral load is undetectable * Creatinine clearance \>= 60 mL/min, unless secondary to renal involvement by lymphoma; for creatinine clearance \< 50 mL/min due to kidney involvement by tumor * Granulocytes/absolute neutrophil count (ANC) \>= 1,000/mm\^3 * Platelets \>= 75,000/mm\^3 (unless these parameters are abnormal secondary to lymphomatous involvement of bone marrow); all participants must cease colony-stimulating factor therapy at least 24 hours prior to institution of cycle 1 chemotherapy * Left ventricular ejection fraction (LVEF) that is at or above the lower institutional limits of normal, as assessed by multiple gated acquisition (MUGA) scan or echocardiogram within the 6 weeks prior to registration * Concurrent radiation, with or without steroids, or steroids alone for emergency conditions secondary to lymphoma (i.e. cord compression, etc.) will be permitted * Female participants must have a negative pregnancy test within 7 days of entering into the study; both men and women of child bearing potential must agree to use adequate methods of contraception for the duration of the treatment; women must avoid pregnancy, and men must avoid fathering children while in the study and for 6 months following the last study drug treatment * Participants on an antiretroviral regimen should be receiving treatment that is in accordance with the current International acquired immune deficiency syndrome (AIDS) Society guidelines; the specific agents are at the discretion of the investigator and use of agents currently available on an expanded access basis is allowed but use of experimental antiretroviral agents or those containing zidovudine (including Combivir and Trizivir) are prohibited; changes to highly active anti-retroviral therapy (HAART) therapy may be made if medically necessary (toxicity, failure of regimen, etc.); antiretroviral naïve participants: participants who are not on HAART at study entry MUST begin therapy (utilizing the above guidelines) AFTER one cycle of chemotherapy has been completed under protocol; changes to HAART therapy may be made if medically necessary (toxicity, failure of regimen, etc.); concurrent therapy with zidovudine or a zidovudine-containing regimen (including Combivir and Trizivir) will be prohibited until 2 months following the participant's completion of chemotherapy as part of this protocol; the use of cobicistat (e.g., Tybost), or cobicistat containing single tablet regimens (e.g., Stribild) is prohibited during concurrent chemotherapy under this protocol; participants taking cobicistat or cobicistat-containing single table regimens must switch to a different agent or regimen prior to enrollment, and will remain on the regimen until at least 2 months following treatment discontinuation; Cobicistat is a pure and potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitor and has the potential to increase the area under the curve (AUC) of CYP3A4 substrates; therefore, both vincristine and doxorubicin would have the potential for drug drug interaction (DDI) with cobicistat since they are CYP3A4 substrates * Participants already receiving erythropoietin or colony-stimulating factor therapy are eligible for participation, although the latter must be discontinued at least 24 hours prior to receiving chemotherapy * Participants must be able to swallow oral medications
Exclusion criteria
* Participants who have received more than one (1) prior cycle of chemotherapy similar to cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) or EPOCH with or without rituximab * Absolute CD4 count of \< 50 cells/ mm\^3 * Presence of second active tumor, other than non-melanoma skin cancer, carcinoma in situ of the cervix, or Kaposi's sarcoma (KS) that requires systemic therapy * Central nervous system (CNS) involvement by lymphoma including parenchymal brain or spinal cord lymphoma or known presence of leptomeningeal disease prior to registration * Participants with viral hepatitis who do not meet the criteria will not be eligible; all participants who present with acute hepatitis B including those with normal transaminases who are HBsAg+ and IgM + for hepatitis core antigen will not be eligible; participants who are hepatitis B core antibody positive are eligible only if they start or are on prophylactic therapy; a hepatitis B viral load should be confirmed negative on all participants who are hepatitis B core antibody positive, but hepatitis B antigen negative; participants refusing to take any anti-hepatitis B therapy during study will also be excluded; participants diagnosed with hepatitis C are eligible if they meet criteria * Pregnant women or nursing mothers * ECOG performance score \>= 3 (Karnofsky performance status \[KPS\] \< 50%) * Expected survival \< 2 months * Unable to comply with the requirements of the protocol, or unable to provide adequate informed consent in the opinion of the principal investigator * Serious, ongoing, non-malignant disease or infection, which in the opinion of the investigator and/or the sponsor would compromise other protocol objectives; participants with active opportunistic infections are ineligible * Major surgery, other than diagnostic surgery, occurring 4 weeks prior to study entry; splenectomy will not be considered an exclusionary major surgery * Rituximab therapy within the 12 months prior to study entry; participants treated with rituximab within 12 months prior to study registration are eligible only if it was given for indications other than the treatment of aggressive lymphoma * Prior cytotoxic chemotherapy or radiotherapy for this lymphoma * History of cutaneous or mucocutaneous reactions, or diseases in the past, due to any cause, severe enough to cause hospitalization or an inability to eat or drink for \> 2 days; this exclusion relates to the long-term possibility of severe cutaneous or mucocutaneous reactions to rituximab that might occur at increased frequency in participants who have had severe skin disease or reactions in the past * Use of zidovudine or cobicistat as part of the HAART regimen (a drug substitution at the time of study entry is allowed) * Any acute, inter-current infection that may interfere with planned protocol treatment; participants with mycobacterium avium will not be excluded from study entry; chronic therapy with potentially myelosuppressive agents is allowed provided that entry hematologic criteria are met * Myocardial infarction (MI) within 6 months prior to study entry, New York Heart Association (NYHA) class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities * Participants should not have taken valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to study enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II) | Up to 6 months | Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study. In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH). |
| Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Up to 5 years | The percentage of participants with AEs and their worst severity will be tabulated for each treatment arm. If a participant has more than one AE, the most severe AE is analyzed. All adverse events will be assessed by the investigator from the first dose of protocol therapy through the post-treatment discontinuation visit. Participants are planned to be treated for a total of 6 cycles (21 day cycle length), or roughly 4 months. After this evaluation, assessment and reporting of AEs will only be required for all grade 5 AEs and any serious AE (SAE) that the investigator considers related to protocol therapy. |
| Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I) | 21 days | Recommended phase II dose of vorinostat is defined as the dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT (Phase I). Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Using a 3+3 design, the recommended phase II dose is defined as the level at which 0/6 or 1/6 patients experiences at dose-limiting toxicity in the first cycle. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Human Herpes Virus (HHV)-8 Viral Load | Baseline up to 12 months | Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. |
| Changes in Human Immunodeficiency Virus (HIV) Viral Load | Baseline up to 12 months | Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. |
| Event-free Survival (EFS) (Phase II) | 1 year | The percentage of participants surviving without events (relapse or death) one year after starting treatment. |
| Change in CD8 Cell Counts (Phase I) | Baseline up to 12 months | Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts. |
| Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | Baseline up to 12 months | Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. |
| Pharmacokinetic Clearance (Phase I) | 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion | Serial plasma samples for pharmacokinetic analysis were collected at 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion. Doxorubicin, etoposide, and vincristine concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The clearance was determined by dividing the drug-infusion rate by the steady-state concentrations, which was the average of the three time points. |
| Tumor Response (Phase I) | Up to 2 years post treatment | The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease |
| Overall Survival (OS) (Phase II) | 1 year | The percentage of participants surviving one year after starting treatment. |
| Changes in Absolute CD4 Cell Counts (Phase I) | Baseline up to 12 months | Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts. |
| Changes in Epstein-Barr Virus (EBV) Viral Load | Baseline up to 12 months | Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Phase I: VR-DA-EPOCH, Dose Level 1 Arm A (VR-DA-EPOCH) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1) | 6 |
| Phase I: VR-DA-EPOCH, Dose Level 2 Arm A (VR-DA-EPOCH) with Vorinostat at 400 mg once a day on days 1-5 of a cycle (Phase I Dose Level 2) | 6 |
| Phase I: VR-CHOP, Dose Level 1 Arm C (VR-CHOP) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1 for low risk participants). This arm was discontinued due to low accrual. | 1 |
| Phase II, V+DA-EPOCH Arm A (VR-DA-EPOCH) at the recommended phase II dose of Vorinostat (300 mg once a day for days 1-5 of a cycle) | 45 |
| Phase II, DA-R-EPOCH Arm B (DA-R-EPOCH), which is the same treatment as Arm A, but without Vorinostat | 45 |
| Total | 103 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Phase II: Randomized Groups | Adverse Event | 0 | 0 | 0 | 5 | 3 |
| Phase II: Randomized Groups | Death | 0 | 0 | 0 | 1 | 1 |
| Phase II: Randomized Groups | Disease progression/relapse on treatment | 0 | 0 | 0 | 5 | 3 |
| Phase II: Randomized Groups | Ineligible | 0 | 0 | 0 | 0 | 1 |
| Phase II: Randomized Groups | Withdrawal by Subject | 0 | 0 | 0 | 1 | 2 |
| Phase I: VR-CHOP, DL 1 | Noncompliant (Cycle 1 not complete) | 0 | 0 | 1 | 0 | 0 |
| Phase I: VR-DA-EPOCH, DL 1 (De-escalate) | Ineligible | 1 | 0 | 0 | 0 | 0 |
| Phase I: VR-DA-EPOCH, DL 2 | Ineligible | 0 | 1 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Phase I: VR-DA-EPOCH, Dose Level 1 | Total | Phase II, DA-R-EPOCH | Phase II, V+DA-EPOCH | Phase I: VR-CHOP, Dose Level 1 | Phase I: VR-DA-EPOCH, Dose Level 2 |
|---|---|---|---|---|---|---|
| Age, Continuous | 45.7 years STANDARD_DEVIATION 12.4 | 47.2 years STANDARD_DEVIATION 9.8 | 45 years STANDARD_DEVIATION 9.2 | 49.2 years STANDARD_DEVIATION 10.1 | 59.5 years STANDARD_DEVIATION 0 | 50.4 years STANDARD_DEVIATION 10.1 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 29 Participants | 13 Participants | 14 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 70 Participants | 30 Participants | 29 Participants | 1 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 4 Participants | 2 Participants | 2 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 3 Participants | 1 Participants | 2 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 22 Participants | 8 Participants | 12 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 12 Participants | 4 Participants | 8 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 4 Participants | 65 Participants | 31 Participants | 23 Participants | 1 Participants | 6 Participants |
| Region of Enrollment United States | 6 Participants | 103 Participants | 45 Participants | 45 Participants | 1 Participants | 6 Participants |
| Sex: Female, Male Female | 0 Participants | 7 Participants | 0 Participants | 6 Participants | 0 Participants | 1 Participants |
| Sex: Female, Male Male | 6 Participants | 96 Participants | 45 Participants | 39 Participants | 1 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 7 | 1 / 7 | 0 / 2 | 13 / 45 | 9 / 46 |
| other Total, other adverse events | 7 / 7 | 6 / 7 | 2 / 2 | 43 / 45 | 43 / 46 |
| serious Total, serious adverse events | 5 / 7 | 3 / 7 | 0 / 2 | 25 / 45 | 21 / 46 |
Outcome results
Primary
Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)
The percentage of participants with AEs and their worst severity will be tabulated for each treatment arm. If a participant has more than one AE, the most severe AE is analyzed. All adverse events will be assessed by the investigator from the first dose of protocol therapy through the post-treatment discontinuation visit. Participants are planned to be treated for a total of 6 cycles (21 day cycle length), or roughly 4 months. After this evaluation, assessment and reporting of AEs will only be required for all grade 5 AEs and any serious AE (SAE) that the investigator considers related to protocol therapy.
Time frame: Up to 5 years
Population: Eligible randomized participants
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Phase II: VR-DA-EPOCH | Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Life-threatening | 37.8 percentage of participants |
| Phase II: VR-DA-EPOCH | Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Moderate | 8.9 percentage of participants |
| Phase II: VR-DA-EPOCH | Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Severe | 20.0 percentage of participants |
| Phase II: VR-DA-EPOCH | Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Mild | 2.2 percentage of participants |
| Phase II: VR-DA-EPOCH | Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Death | 28.9 percentage of participants |
| Phase II: DA-R-EPOCH | Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Mild | 0 percentage of participants |
| Phase II: DA-R-EPOCH | Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Death | 20.0 percentage of participants |
| Phase II: DA-R-EPOCH | Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Life-threatening | 28.9 percentage of participants |
| Phase II: DA-R-EPOCH | Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Severe | 31.1 percentage of participants |
| Phase II: DA-R-EPOCH | Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II) | Moderate | 17.8 percentage of participants |
Primary
Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)
Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study. In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH).
Time frame: Up to 6 months
Population: Reviewed responses from participants who completed at least one cycle of treatment. In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH).~In phase I, patients in DA-R-EPOCH were not included in the analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase II: VR-DA-EPOCH | Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II) | 67.5 percentage of participants |
| Phase II: DA-R-EPOCH | Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II) | 76.2 percentage of participants |
Primary
Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)
Recommended phase II dose of vorinostat is defined as the dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT (Phase I). Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Using a 3+3 design, the recommended phase II dose is defined as the level at which 0/6 or 1/6 patients experiences at dose-limiting toxicity in the first cycle.
Time frame: 21 days
Population: Eligible Phase I Arm A (VR-DA-EPOCH) participants who completed at least 1 cycle of treatment. This arm includes participants treated at 300 mg once a day (n=6) or 400 mg once a day (n=6) of Vorinostat for days 1-5.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase II: VR-DA-EPOCH | Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I) | 300 Mg per day of Vorinostat |
Secondary
Change in CD8 Cell Counts (Phase I)
Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts.
Time frame: Baseline up to 12 months
Population: Eligible participants who returned for follow-up with evaluable data.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Phase II: VR-DA-EPOCH | Change in CD8 Cell Counts (Phase I) | End of cycle 2 | 35.5 cells/mm^3 |
| Phase II: VR-DA-EPOCH | Change in CD8 Cell Counts (Phase I) | Treatment discontinuation | -164.5 cells/mm^3 |
| Phase II: VR-DA-EPOCH | Change in CD8 Cell Counts (Phase I) | 6-month follow-up | -56 cells/mm^3 |
| Phase II: VR-DA-EPOCH | Change in CD8 Cell Counts (Phase I) | 12-month follow-up | 604 cells/mm^3 |
| Phase II: DA-R-EPOCH | Change in CD8 Cell Counts (Phase I) | 12-month follow-up | 154 cells/mm^3 |
| Phase II: DA-R-EPOCH | Change in CD8 Cell Counts (Phase I) | End of cycle 2 | -115 cells/mm^3 |
| Phase II: DA-R-EPOCH | Change in CD8 Cell Counts (Phase I) | 6-month follow-up | 275 cells/mm^3 |
| Phase II: DA-R-EPOCH | Change in CD8 Cell Counts (Phase I) | Treatment discontinuation | 211 cells/mm^3 |
| Phase I: VR-CHOP, Dose Level 1 | Change in CD8 Cell Counts (Phase I) | 12-month follow-up | 128 cells/mm^3 |
| Phase I: VR-CHOP, Dose Level 1 | Change in CD8 Cell Counts (Phase I) | Treatment discontinuation | -81 cells/mm^3 |
| Phase I: VR-CHOP, Dose Level 1 | Change in CD8 Cell Counts (Phase I) | 6-month follow-up | -16 cells/mm^3 |
| Phase I: VR-CHOP, Dose Level 1 | Change in CD8 Cell Counts (Phase I) | End of cycle 2 | -172 cells/mm^3 |
Secondary
Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)
Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values.
Time frame: Baseline up to 12 months
Population: Eligible participants who returned for follow-up with evaluable data.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Phase II: VR-DA-EPOCH | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | 6-month follow-up | -55116 copies per milliliter |
| Phase II: VR-DA-EPOCH | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | 12-month follow-up | 0 copies per milliliter |
| Phase II: VR-DA-EPOCH | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | Treatment discontinuation | -4517 copies per milliliter |
| Phase II: VR-DA-EPOCH | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | End of cycle 2 | -14518 copies per milliliter |
| Phase II: DA-R-EPOCH | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | End of cycle 2 | -12.5 copies per milliliter |
| Phase II: DA-R-EPOCH | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | Treatment discontinuation | 0 copies per milliliter |
| Phase II: DA-R-EPOCH | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | 12-month follow-up | 0 copies per milliliter |
| Phase II: DA-R-EPOCH | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | 6-month follow-up | 0 copies per milliliter |
| Phase I: VR-CHOP, Dose Level 1 | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | 12-month follow-up | 0 copies per milliliter |
| Phase I: VR-CHOP, Dose Level 1 | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | End of cycle 2 | 28 copies per milliliter |
| Phase I: VR-CHOP, Dose Level 1 | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | Treatment discontinuation | 0 copies per milliliter |
| Phase I: VR-CHOP, Dose Level 1 | Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I) | 6-month follow-up | 0 copies per milliliter |
Secondary
Changes in Absolute CD4 Cell Counts (Phase I)
Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts.
Time frame: Baseline up to 12 months
Population: Eligible participants who completed at least 1 cycle of treatment with evaluable data.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Phase II: VR-DA-EPOCH | Changes in Absolute CD4 Cell Counts (Phase I) | End of cycle 2 | 92 cell/mm^3 |
| Phase II: VR-DA-EPOCH | Changes in Absolute CD4 Cell Counts (Phase I) | Treatment discontinuation | -39 cell/mm^3 |
| Phase II: VR-DA-EPOCH | Changes in Absolute CD4 Cell Counts (Phase I) | 6-month follow-up | 76 cell/mm^3 |
| Phase II: VR-DA-EPOCH | Changes in Absolute CD4 Cell Counts (Phase I) | 12-month follow-up | 169 cell/mm^3 |
| Phase II: DA-R-EPOCH | Changes in Absolute CD4 Cell Counts (Phase I) | 12-month follow-up | 31 cell/mm^3 |
| Phase II: DA-R-EPOCH | Changes in Absolute CD4 Cell Counts (Phase I) | End of cycle 2 | -9 cell/mm^3 |
| Phase II: DA-R-EPOCH | Changes in Absolute CD4 Cell Counts (Phase I) | 6-month follow-up | 31 cell/mm^3 |
| Phase II: DA-R-EPOCH | Changes in Absolute CD4 Cell Counts (Phase I) | Treatment discontinuation | -29 cell/mm^3 |
| Phase I: VR-CHOP, Dose Level 1 | Changes in Absolute CD4 Cell Counts (Phase I) | 12-month follow-up | -84 cell/mm^3 |
| Phase I: VR-CHOP, Dose Level 1 | Changes in Absolute CD4 Cell Counts (Phase I) | Treatment discontinuation | -190 cell/mm^3 |
| Phase I: VR-CHOP, Dose Level 1 | Changes in Absolute CD4 Cell Counts (Phase I) | 6-month follow-up | -175 cell/mm^3 |
| Phase I: VR-CHOP, Dose Level 1 | Changes in Absolute CD4 Cell Counts (Phase I) | End of cycle 2 | -218 cell/mm^3 |
Secondary
Changes in Epstein-Barr Virus (EBV) Viral Load
Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load.
Time frame: Baseline up to 12 months
Population: Median Change from the baseline and IQR were calculated. The measurement unit is IU/mL.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Phase II: VR-DA-EPOCH | Changes in Epstein-Barr Virus (EBV) Viral Load | End of Cycle 2 | -0.61 IU/mL |
| Phase II: VR-DA-EPOCH | Changes in Epstein-Barr Virus (EBV) Viral Load | At treatment discontinuation | -2.9 IU/mL |
| Phase II: VR-DA-EPOCH | Changes in Epstein-Barr Virus (EBV) Viral Load | 6-month follow-up | -1.55 IU/mL |
| Phase II: VR-DA-EPOCH | Changes in Epstein-Barr Virus (EBV) Viral Load | 12-month follow-up | -0.56 IU/mL |
| Phase II: DA-R-EPOCH | Changes in Epstein-Barr Virus (EBV) Viral Load | 12-month follow-up | -2.7 IU/mL |
| Phase II: DA-R-EPOCH | Changes in Epstein-Barr Virus (EBV) Viral Load | 6-month follow-up | 0 IU/mL |
| Phase II: DA-R-EPOCH | Changes in Epstein-Barr Virus (EBV) Viral Load | At treatment discontinuation | -0.28 IU/mL |
| Phase II: DA-R-EPOCH | Changes in Epstein-Barr Virus (EBV) Viral Load | End of Cycle 2 | 0 IU/mL |
| Phase I: VR-CHOP, Dose Level 1 | Changes in Epstein-Barr Virus (EBV) Viral Load | 6-month follow-up | 0 IU/mL |
| Phase I: VR-CHOP, Dose Level 1 | Changes in Epstein-Barr Virus (EBV) Viral Load | 12-month follow-up | 0 IU/mL |
| Phase I: VR-CHOP, Dose Level 1 | Changes in Epstein-Barr Virus (EBV) Viral Load | At treatment discontinuation | 0 IU/mL |
| Phase I: VR-CHOP, Dose Level 1 | Changes in Epstein-Barr Virus (EBV) Viral Load | End of Cycle 2 | 0 IU/mL |
| Phase I: VR-DA-EPOCH, Dose Level 2 | Changes in Epstein-Barr Virus (EBV) Viral Load | 12-month follow-up | -1.15 IU/mL |
| Phase I: VR-DA-EPOCH, Dose Level 2 | Changes in Epstein-Barr Virus (EBV) Viral Load | End of Cycle 2 | -2436.1 IU/mL |
| Phase I: VR-DA-EPOCH, Dose Level 2 | Changes in Epstein-Barr Virus (EBV) Viral Load | At treatment discontinuation | -1.92 IU/mL |
| Phase I: VR-DA-EPOCH, Dose Level 2 | Changes in Epstein-Barr Virus (EBV) Viral Load | 6-month follow-up | -1.92 IU/mL |
Secondary
Changes in Human Herpes Virus (HHV)-8 Viral Load
Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load.
Time frame: Baseline up to 12 months
Population: Outcome measure is the difference between the baseline and specific time points (End of Cycle 2, Treatment discontinuation, 6-month, and 12-month follow-ups.~Only a few differences can be calculated.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Phase II: VR-DA-EPOCH | Changes in Human Herpes Virus (HHV)-8 Viral Load | 12-month follow-up | 0 copies per 100uL |
| Phase II: DA-R-EPOCH | Changes in Human Herpes Virus (HHV)-8 Viral Load | At treatment discontinuation | 0 copies per 100uL |
| Phase II: DA-R-EPOCH | Changes in Human Herpes Virus (HHV)-8 Viral Load | 6-month follow-up | 0 copies per 100uL |
| Phase II: DA-R-EPOCH | Changes in Human Herpes Virus (HHV)-8 Viral Load | 12-month follow-up | 0 copies per 100uL |
| Unknown | Changes in Human Herpes Virus (HHV)-8 Viral Load | End of Cycle 2 | — copies per 100uL |
Secondary
Changes in Human Immunodeficiency Virus (HIV) Viral Load
Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values.
Time frame: Baseline up to 12 months
Population: Phase II participants who returned for follow-up with evaluable data.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Phase II: VR-DA-EPOCH | Changes in Human Immunodeficiency Virus (HIV) Viral Load | End of Cycle 2 | -20 median change in copies per mL |
| Phase II: VR-DA-EPOCH | Changes in Human Immunodeficiency Virus (HIV) Viral Load | At treatment discontinuation | -87 median change in copies per mL |
| Phase II: VR-DA-EPOCH | Changes in Human Immunodeficiency Virus (HIV) Viral Load | 6-month follow-up | -20 median change in copies per mL |
| Phase II: VR-DA-EPOCH | Changes in Human Immunodeficiency Virus (HIV) Viral Load | 12-month follow-up | 0 median change in copies per mL |
| Phase II: DA-R-EPOCH | Changes in Human Immunodeficiency Virus (HIV) Viral Load | 12-month follow-up | -20 median change in copies per mL |
| Phase II: DA-R-EPOCH | Changes in Human Immunodeficiency Virus (HIV) Viral Load | End of Cycle 2 | -25 median change in copies per mL |
| Phase II: DA-R-EPOCH | Changes in Human Immunodeficiency Virus (HIV) Viral Load | 6-month follow-up | -18 median change in copies per mL |
| Phase II: DA-R-EPOCH | Changes in Human Immunodeficiency Virus (HIV) Viral Load | At treatment discontinuation | -22.5 median change in copies per mL |
Secondary
Event-free Survival (EFS) (Phase II)
The percentage of participants surviving without events (relapse or death) one year after starting treatment.
Time frame: 1 year
Population: Eligible randomized participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase II: VR-DA-EPOCH | Event-free Survival (EFS) (Phase II) | 75.6 percentage of participants |
| Phase II: DA-R-EPOCH | Event-free Survival (EFS) (Phase II) | 82.2 percentage of participants |
Secondary
Overall Survival (OS) (Phase II)
The percentage of participants surviving one year after starting treatment.
Time frame: 1 year
Population: Eligible randomized participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase II: VR-DA-EPOCH | Overall Survival (OS) (Phase II) | 77.6 percentage of participants |
| Phase II: DA-R-EPOCH | Overall Survival (OS) (Phase II) | 86.7 percentage of participants |
Secondary
Pharmacokinetic Clearance (Phase I)
Serial plasma samples for pharmacokinetic analysis were collected at 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion. Doxorubicin, etoposide, and vincristine concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The clearance was determined by dividing the drug-infusion rate by the steady-state concentrations, which was the average of the three time points.
Time frame: 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion
Population: Phase I participants with evaluable pharmacokinetic data
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Phase II: VR-DA-EPOCH | Pharmacokinetic Clearance (Phase I) | Doxorubicin | 78.6 Liter/hour | Standard Deviation 48 |
| Phase II: VR-DA-EPOCH | Pharmacokinetic Clearance (Phase I) | Etoposide | 3.0 Liter/hour | Standard Deviation 1.6 |
| Phase II: VR-DA-EPOCH | Pharmacokinetic Clearance (Phase I) | Vincristine | 22.4 Liter/hour | Standard Deviation 10.2 |
| Phase II: DA-R-EPOCH | Pharmacokinetic Clearance (Phase I) | Doxorubicin | 76.0 Liter/hour | Standard Deviation 47.9 |
| Phase II: DA-R-EPOCH | Pharmacokinetic Clearance (Phase I) | Etoposide | 2.4 Liter/hour | Standard Deviation 0.7 |
| Phase II: DA-R-EPOCH | Pharmacokinetic Clearance (Phase I) | Vincristine | 16.8 Liter/hour | Standard Deviation 8.9 |
Secondary
Tumor Response (Phase I)
The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease
Time frame: Up to 2 years post treatment
Population: Eligible participants who completed at least 1 cycle of treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Phase II: VR-DA-EPOCH | Tumor Response (Phase I) | Complete response | 83.3 percentage of participants |
| Phase II: VR-DA-EPOCH | Tumor Response (Phase I) | Partial Response | 16.7 percentage of participants |
| Phase II: DA-R-EPOCH | Tumor Response (Phase I) | Partial Response | 16.7 percentage of participants |
| Phase II: DA-R-EPOCH | Tumor Response (Phase I) | Complete response | 83.3 percentage of participants |
| Phase I: VR-CHOP, Dose Level 1 | Tumor Response (Phase I) | Complete response | 100 percentage of participants |
| Phase I: VR-CHOP, Dose Level 1 | Tumor Response (Phase I) | Partial Response | 0 percentage of participants |